Vebreltinib for Previously Treated Astrocytoma, IDH-Mutant, Grade 4, and Glioblastoma, IDH Wild-Type with PTPRZ1-MET Fusion Gene: A Multicenter, Phase III Randomized, Open-Label Trial - PubMed
a day ago
- #glioblastoma
- #vebreltinib
- #clinical-trial
- Vebreltinib evaluated in a Phase III trial for high-grade gliomas with PTPRZ1-MET fusion gene.
- Significant improvement in overall survival (OS) with vebreltinib vs. control (6.3 vs. 3.4 months).
- IDH-mutant subgroup showed median OS of 7.7 months with vebreltinib vs. 3.3 months in control.
- Patients with tumor diameter ≤3.0 cm had median OS of 32.5 months with vebreltinib vs. 4.2 months.
- Progression-free survival (PFS) and objective response rate (ORR) were better with vebreltinib.
- Safety profile was manageable with no treatment-related deaths reported.
- Study sponsored by Beijing Pearl Biotechnology Co. Ltd., with no competing interests declared.